# US 2021/0275489 A1 · Platinum-based amphiphile prodrugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275489 A1
- Document ID: US20210275489A1
- Status: Published application
- Kind: A1
- Application number: 17/256,082
- Filed: 2019-06-21
- Published: 2021-09-09
- Earliest claimed: 2018-06-21
- Assignees: Nanomed Holdings Pty Ltd
- Applicants: Nanomed Holdings Pty Ltd
- Inventors: Minoo Jalili MOGHADDAM; Xiaojuan GONG; Ross Cyril SMITH
- Web page: https://patentgrep.com/patent/US20210275489A1

## CPC

- A61K 31/282: Platinum compounds
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61K 47/543: {Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine}
- A61P 35/00: Antineoplastic agents
- C07F 15/0093: {without a metal-carbon linkage}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The present invention relates to platinum (IV) prodrug lipid-based amphiphiles and compositions thereof. In particular, it relates to cisplatin, oxaliplatin and carboplatin prodrugs with the capacity to make stable liquid crystalline nanoparticles and crystalline nanoparticles, and uses thereof to treat cancer in animals, including humans.

## Claims

### Claim 1

A prodrug of general formula I:
X1—Y1—A-(Y2)n—X2 (I)
wherein A is an oxidised platinum (IV)-based therapeutically active agent;
Y1 and Y2 are independently selected cleavable bonds between X1 and X2, respectively, and A;
n=0 or 1, wherein when X2 is a substituent according to formula (a), (b), or (c), n is 1;
X1 is selected from the group consisting of a substituent according to formula (a), a substituent according to formula (b), and a substituent according to formula (c):
R— (a)
R—S— (b)
R—S-L (c)
X2 is selected from the group consisting of H, a substituent according to formula (a), a substituent according to formula (b), and a substituent according to formula (c):
R— (a)
R—S— (b)
R—S-L (c)
wherein
R is selected from the group consisting of alkyl, alkenyl, alkynyl, branched alkyl, branched alkenyl, branched alkynyl, substituted alkyl, substituted alkenyl, substituted alkynyl groups, and their analogues;
S is selected from the group consisting of (polyethylene glycol)m, wherein m=1-10, an amino acid, and an ethanolamide functionalised amino acid;
L is a linker group that is covalently attached to S—R at one attachment site and to the therapeutically active agent A at a second attachment site via the bond Y to A.

### Claim 2 (depends on 1)

A prodrug according to claim 1, wherein the oxidised platinum (IV)-based therapeutically active agent is selected from the group consisting of cisplatin, oxaliplatin, carboplatin, and derivatives thereof.

### Claim 3 (depends on 1)

A prodrug according to claim 1, wherein the general formula (I) is a compound according to formula (II):

### Claim 4 (depends on 3)

A prodrug according to claim 3, wherein the compound according to Formula (II) is selected from the group consisting of:

### Claim 5 (depends on 1)

A prodrug according to claim 1, wherein the general formula (I) is a compound according to formula (III):

### Claim 6 (depends on 5)

A prodrug according to claim 5, wherein the compound according to Formula (III) is selected from the group consisting of:

### Claim 7 (depends on 1)

A prodrug according to claim 1, wherein the general formula (I) is a compound according to formula (IV):

### Claim 8 (depends on 7)

A prodrug according to claim 7, wherein the compound according to Formula (IV) is selected from the group consisting of:

### Claim 9 (depends on 1)

A self-assembled structure formed from the prodrug of claim 1, wherein the structure exhibits a mesophase under physiological conditions selected from the group consisting of: lamellar, bicontinuous cubic phase, hexagonal and sponge phases.

### Claim 10 (depends on 9)

A self-assembled structure according to claim 9, wherein the mesophase exhibited is lamellar and inverse phases.

### Claim 11 (depends on 1)

A self-assembled structure formed from the prodrug of claim 1, wherein the structure is a solid lipid particle.

### Claim 12 (depends on 9)

A self-assembled structure according to claim 9, further comprising a component selected from the group consisting of: phospholipid, cholesterol, glycerol lipid, other prodrug amphiphile, hydrophobic drugs and combinations thereof.

### Claim 13

A method of modulating the bioavailability and release of a platinum-based therapeutically active agent or an agent capable of being metabolised in vivo to a platinum-based therapeutically active agent, the method comprising covalently linking an oxidised platinum (IV)-based therapeutically active agent, A, to at least one tail component, X, to form an amphiphile capable of self-assembling into a self-assembled structure under physiological conditions, and wherein the amphiphile is cleavable in vivo to release the therapeutically active agent, wherein the amphiphile is of general formula (I):
X1—Y1-A-(Y2)n—X2 (I)
wherein
Y1 and Y2 are independently selected cleavable bonds between X1 and X2, respectively, and A;
n=0 or 1, wherein when X2 is a substituent according to formula (a), (b), or (c), n is 1;
X1 is selected from the group consisting of a substituent according to formula (a), a substituent according to formula (b), and a substituent according to formula (c):
R— (a)
R—S— (b)
R—S-L (c)
X2 is selected from the group consisting of H, a substituent according to formula (a), a substituent according to formula (b), and a substituent according to formula (c):
R— (a)
R—S— (b)
R—S-L (c)
wherein
R is selected from the group consisting of alkyl, alkenyl, alkynyl, branched alkyl, branched alkenyl, branched alkynyl, substituted alkyl, substituted alkenyl, substituted alkynyl groups, and their analogues;
S is selected from the group consisting of (polyethylene glycol)m, wherein m=1-10, an amino acid, and an ethanolamide functionalised amino acid;
L is a linker group that is covalently attached to S—R at one attachment site and to the therapeutically active agent A at a second attachment site via the bond Y to A.

### Claim 14 (depends on 13)

A method according to claim 13, wherein the amphiphile of general formula (I) is a compound according to formula (II):

### Claim 15 (depends on 13)

A method according to claim 13, wherein the amphiphile of general formula (I) is a compound according to formula (III):

### Claim 16 (depends on 13)

A method according to claim 13, wherein the amphiphile of general formula (I) is a compound according to formula (IV):

### Claim 17 (depends on 13)

A method according to claim 13, wherein the amphiphile is a substrate for an enzymatic or a chemical reaction that promotes formation of an active form of the therapeutic agent.

### Claim 18 (depends on 9)

A method of treating or preventing cancer in a person in need thereof, including administering to the person a self-assembled structure according to claim 9.
